Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREK-DX: Eblasakimab in Dupilumab-Experienced AD
NCT05694884Phase 2Recruiting
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of eblasakimab in atopic dermatitis (AD), sponsored by ASLAN Pharmaceuticals. Started Dec 2022; status: recruiting.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05694884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694884.